Suspension Cell Culture

Overview

Developing and optimizing the bioprocess in lab-scale bioreactor is crucial in biopharmaceutical industry. It requires in-depth bioprocessing expertise, knowledge, and hands-on experience in cell culture development as well as robust technology platform, which enables rapid and predictable tech-transfer to manufacturing scale for recombinant therapeutic protein production.

Esco Aster has an end-to-end CDMO services from gene to therapeutic product and delivers client success to preclinical trial, investigational new drug (IND) and clinical trial faster with flexibility.

The facility includes GLP standards laboratory, bioprocessing equipment of cutting-edge technology coupled with our experts, and in-house product release testing capabilities. Moreover, there are to support client requirements for cell line creation, process development and optimization, technology transfer, GMP cell banking and manufacturing production.


Our Process Overview

Our services include but not limited to the following activities:
Culture Media Development Platform

Our Capabilities

Esco Aster provides CDMO services to cell culture process develop and manufacture production cell lines used for early-stage research to preclinical and clinical phase trial. Our cell culture process development services support clients' specific requirements for cell culture process development and optimization regardless of its current development status, whether the product is in early-stage development or ready to launch, as well as media and feed screening and process parameter optimization.

Our capabilities include process development services from upstream to downstream bioprocessing, analytical testing via process analytical technology (PAT) as well as chemistry, manufacturing, and controls (CMC) regulatory approval of your products.

Our Capabilities

Media and Feed Screening

Esco Aster offers clients the media screening and feed optimization using a Design-of-Experiment (DOE) approach in the scale-down model. The study design consisted of the desired experimental conditions combines the animal component-free chemically defined (ACFCD) cell culture media with main feed and feed supplements, along with feed volumes and frequency of addition optimized to maximize product productivity over a time course.

Individual experimental conditions are evaluated and spent media are analyzed statistically, with the best conditions chosen for further development.

Media and Feed Screening

Upstream Process Development and Parameter Optimization

Esco Aster can develop the cell culture operation in our proprietary bioreactors (BioXcell®) with a deep understanding of the process and a state-of-the-art cell culture development facility. Through the investigation of interactions between parameters such as temperature, pH, gas flow rate, dissolved oxygen (DO), and agitation, we can further optimize the bioprocess for product quality and productivity improvement based on biomass monitors, cell counter, metabolic analysis following Quality-by-Design (QbD) standards.

Ultimately, implementation of an optimized process at a larger lab-scale bioreactor for confirmation run ensures production processes are scalable and consistent.

BioXcell

Technology Transfer

Esco Aster generates production process for reliable support of our clients’ preclinical, clinical, and commercial supply, and our development experts and bioreactor engineers provide process protocols, scale-up protocol, process characterization protocol, technology transfer document, development summary report, scale-up report, risk assessment, process characterization report.

Robust and scalable production process aims at achieving a low cost, shortened timeline, high productivity, reproducibility, and consistency in drug development for the manufacture of the biopharmaceuticals for clinical and commercial production.

Technology Transfer